Research Papers:

Impact of autoimmune diseases on outcome of patients with early breast cancer

Carmen Criscitiello, Vincenzo Bagnardi, Angela Esposito, Lucia Gelao, Barbara Santillo, Giulia Viale, Nicole Rotmensz, Aron Goldhirsch and Giuseppe Curigliano _

PDF  |  HTML  |  How to cite

Oncotarget. 2016; 7:51184-51192. https://doi.org/10.18632/oncotarget.9966

Metrics: PDF 1684 views  |   HTML 2529 views  |   ?  


Carmen Criscitiello1, Vincenzo Bagnardi2,3, Angela Esposito1, Lucia Gelao1, Barbara Santillo2, Giulia Viale1, Nicole Rotmensz2, Aron Goldhirsch1,4, Giuseppe Curigliano1

1Division of Experimental Therapeutics, Istituto Europeo di Oncologia, Milano, Italy

2Division of Epidemiology and Biostatistics, Istituto Europeo di Oncologia, Milano, Italy

3Department of Statistics and Quantitative Methods, University of Milan-Bicocca, Milano, Italy

4Breast Cancer Program, Istituto Europeo di Oncologia, Milano, Italy

Correspondence to:

Giuseppe Curigliano, email: [email protected]

Keywords: autoimmunity, early breast cancer, endocrine therapy, clinical outcome, immunology

Received: February 11, 2016     Accepted: May 28, 2016     Published: June 13, 2016


Our aim was to analyze the impact of a concurrent autoimmune disease on outcome of patients with early breast cancer. We reviewed medical charts of patients with a diagnosis of autoimmune diseases (AD) among a population of 17.153 cases. We categorized ADs as endocrine, rheumatic, systemic, neurological diseases and vasculitis. For each patient in the study group, we matched 2 patients. The events to determine overall survival (OS) and disease free survival (DFS) were identified from follow-up data. We identified 279 (1.62%) patients with early breast cancer and concurrent ADs. The median follow-up was 7.0 years. The 10-year OS rate was 86% (95% CI, 80% to 91%) in the study group and 90% (95% CI, 86% to 93%) for the control group (p = 0.011). In patients with ER positive/HER2 negative subtype a worse OS was observed in the study group when compared to the control group (p = 0.0046); this difference remained statistically significant when the analysis was restricted to breast cancer mortality (p = 0.045). The 10-year DFS rate was 69% (95% CI, 61% to 76%) in the study group and 72% (95% CI, 66% to 77%) for the control group (p = 0.22). Autoimmunity at diagnosis of early breast cancer is associated with worse survival.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 9966